Skip to main content

Genomic Solutions to Slash 25% of Jobs; Future of Proteomics Effort Uncertain

NEW YORK, Sept. 7 – Proteomics and microarray developer Genomic Solutions said on Friday it plans to cut 25 percent of its workforce and restructure its business to help it become profitable by the first quarter of next year.

The company said in a statement that the restructuring includes the closing of an R&D and manufacturing facility in Lansing, Michigan. Jobs associated with that space will be transplanted to the company’s headquarters in Ann Arbor.

Jobs in Michigan and in Genomic Solutions’ offices in the UK will be eliminated by the end of the fourth quarter this year.

The company said its proteomic contract research business will either be spun out to an internal management group as a stand-alone business with Genomic Solutions as a minority shareholder, or will be sold outright.

Genomic Solutions also said it intends to retain chemical, reagent, and accessory manufacturing operations that share facilities with the proteomic contract research center. The company will continue to offer genomic research services in its existing in-house genomic laboratory.

“We are taking steps now to accelerate achievement of Genomic Solutions' financial performance goals,” Jeffrey S. Williams, the firm’s president and chief executive officer, said in the statement. “It is more than simply cutting costs--it is a fundamental restructuring of all of our available resources to further build our position as one of the leading suppliers of DNA microarray and proteomic systems in the life sciences marketplace.”

Separately on Friday, Genomic Solutions said it plans to purchase privately held Cartesian Technologies in a cash and stock deal that the struggling company hopes will buttress its foothold in the automation tools market.

Terms of the deal call for Genomic Solutions to issue 6.8 million shares of common stock, options to buy 449,319 shares of common stock and $2.5 million in cash.

“Enhanced revenue and cost reduction opportunities, plus the inherent product cross-selling opportunities, make this acquisition a timely, ideal fit for Genomic Solutions,” Williams said in a separate statement.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.